- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
Wall Street JournalEN
L
LXRX
Lexicon Pharmaceuticals Inc
0.72
0.05+7.55%After Hours: 0.7206 0.00 0.00%18:40 06/17 EDT
OPEN/PREV CLOSE0.6650/0.6700
TODAY RANGE0.6547-0.7500
VOL4.63M
MARKET CAP261.71M
52 WEEK RANGE0.2836-2.450
AVG VOL (3M)13.30M
% TURNOVER1.27%
TURNOVER--
P/E (TTM)-1.4009
% RANGE14.18%
EPS(TTM)-0.5144
P/E(FORWARD)-2.0887
P/B2.127
BVPS0.3388
DIVIDEND--
P/S8.38
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP258.49M
SHARES OUTSTANDING363.18M
NEXT EARNINGS07/30-08/04
FREE FLOAT358.72M
LOT SIZE1
EX-DATE05/21/2015
News
Press Releases
Financial Reports
Profile
Simply Wall St·4d ago
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%
NASDAQ·06/10 13:08
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
NASDAQ·06/06 15:52
KURA Stock Rises More Than 15% This Past Week: Here's Why
NASDAQ·06/06 15:35
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
NASDAQ·06/05 17:03
Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?
NASDAQ·06/05 16:55
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success
NASDAQ·06/04 16:17
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
TipRanks·06/03 20:40
Lexicon Pharmaceuticals Holds Annual Stockholder Meeting
NASDAQ·06/03 15:14
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
NASDAQ·06/03 13:43
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
NASDAQ·06/02 14:53
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
NASDAQ·05/30 14:20
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
NASDAQ·05/30 12:59
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
NASDAQ·05/29 15:44
BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications
Same Industry
Name/Symbol
Change%
Price